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Abstract
The aim of this study is to determine the efficacy of neoadjuvant chemotherapy
(NAC) with gemcitabine (GEM) in combination with fluorescence-guided surgery
(FGS) on a pancreatic cancer patient derived orthotopic xenograft (PDOX) model.
A PDOX model was established from a CA19-9-positive, CEA-negative tumor from
a patient who had undergone a pancreaticoduodenectomy for pancreatic
adenocarcinoma. Mice were randomized to 4 groups: bright light surgery (BLS)
only; BLS+NAC; FGS only; and FGS+NAC. An anti-CA19-9 or anti-CEA antibody
conjugated to DyLight 650 was administered intravenously via the tail vein of mice
with the pancreatic cancer PDOX 24 hours before surgery. The PDOX was brightly
labeled with fluorophore-conjugated anti-CA19-9, but not with a fluorophore-
conjugated anti-CEA antibody. FGS was performed using the fluorophore-
conjugated anti-CA19-9 antibody. FGS had no benefit over BLS to prevent
metastatic recurrence. NAC in combination with BLS did not convey an advantage
over BLS to prevent metastatic recurrence. However, FGS+NAC significantly
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reduced the metastatic recurrence frequency to one of 8 mice, compared to FGS
only after which metastasis recurred in 6 out of 8 mice, and BLS+NAC with
metastatic recurrence in 7 out of 8 mice (p50.041). Thus NAC in combination with
FGS can reduce or even eliminate metastatic recurrence of pancreatic cancer
sensitive to NAC. The present study further emphasizes the power of the PDOX
model which enables metastasis to occur and thereby identify the efficacy of NAC
in combination with FGS on metastatic recurrence.
Introduction
Complete tumor resection improves overall survival of pancreatic cancer patients,
which is presently 5% at five years [1]. Metastatic relapse often occurs following
attempted curative resection of the primary tumor as a result of invisible
microscopic tumor deposits left behind. Making tumors fluoresce offers great
advantages for tumor detection during surgery in order to achieve complete
resection [2, 3]. We have previously shown that fluorescence-guided surgery
(FGS) for pancreatic cancer decreased the residual tumor burden and improved
overall and disease-free survival in mouse models using fluorescently-labeled
human pancreatic cancer cell lines [4–6].
Patient-derived orthotopic xenografts (PDOX) recapitulate the biological
characteristics of the disease of origin, including metastases [7–11] and are a
clinically-relevant model for fluorescence-guided surgery [4, 12–14].
Recently, many studies reported positive outcomes with neoadjuvant
chemotherapy (NAC) of pancreatic cancer [15–17]. NAC allows for the
identification of those patients with rapidly progressive metastatic disease at the
time of preoperative restaging, and can increase the R0 resection rate and reduce
the risk of local tumor recurrence [15]. However, a significant number of patients
still develop recurrent disease immediately after NAC treatment and subsequent
surgical resection [16–18]. Therefore, new strategies in addition to NAC are
needed to reduce the recurrence of pancreatic cancer. In this study, we determined
the efficacy of CA19-9 conjugated with a fluorescent dye to illuminate pancreatic
cancer PDOXs for FGS in combination with NAC.
Materials and Methods
Animals
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were
used in this study. Mice were kept in a barrier facility under HEPA filtration. Mice
were fed with an autoclaved laboratory rodent diet. All mouse surgical procedures
and imaging were performed with the animals anesthetized by intramuscular
injection of 50% ketamine, 38% xylazine, and 12% acepromazine maleate
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(0.02 ml). Animals received buprenorphine (0.10 mg/kg ip) immediately prior to
surgery and once a day over the next 3 days to ameliorate pain. CO2 inhalation
was used for euthanasia of all animals at 90 days after surgery. To ensure death
following CO2 asphyxiation, cervical dislocation was performed. All animal
studies were conducted with an AntiCancer, Inc. Institutional Animal Care and
Use Committee (IACUC)-protocol specifically approved for this study and in
accordance with the principals and procedures outlined in the National Institute
of Health Guide for the Care and Use of Animals under Assurance Number
A3873-1.
Establishment of patient derived orthotopic xenograft (PDOX) of
pancreatic cancer
Pancreatic cancer patient tumor tissues were obtained at surgery and cut into
fragments (3-mm3) and transplanted subcutaneously in nude mice [7, 19]. The
subcutaneous tumors were then passaged in nude mice both orthotopically and
subcutaneously. All patients provided written informed consent and samples were
procured and initially transplanted in NOD/SCID under the approval of the
Institutional Review Board of MD Anderson Cancer Center.
Orthotopic tumor implantation
A small 6- to 10-mm transverse incision was made on the left flank of the mouse
through the skin and peritoneum. The tail of the pancreas was exposed through
this incision, and a single 3-mm3 tumor fragment from subcutaneous tumors was
sutured to the tail of the pancreas using 8-0 nylon surgical sutures (Ethilon;
Ethicon Inc., NJ, USA). On completion, the tail of the pancreas was returned to
the abdomen, and the incision was closed in one layer using 6-0 nylon surgical
sutures (Ethilon) [7, 20].
Antibody conjugation and tumor labeling
Monoclonal antibodies specific for carbohydrate antigen 19-9 (CA19-9) and
carcinoembryonic antigen (CEA) were obtained from Abcam Inc. (Cambridge,
MA, USA) and (Aragen Bioscience, Inc. (Morgan Hill, CA, USA), respectively.
The antibodies were labeled with the DyLight 650 Protein Labeling Kit
(Thermofisher Scientific, Waltham, MA, USA) according to the manufacturer’s
instructions [5, 12, 21]. To determine if the anti-CA19-9 antibody, conjugated
with DyLight 650 (anti-CA19-9-650), and the anti-CEA antibody, conjugated with
DyLight650 (anti-CEA-650), could label the pancreatic tumor in vivo, 50 mg of
anti-CA19-9-650 or anti-CEA-650 were injected into the tail vein of the mice with
subcutaneous pancreatic tumors. Twenty-four hours later, whole body images
were obtained with the OV100 Small Animal Variable Magnification Imaging
System (Olympus, Tokyo, Japan).
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Neoadjuvant chemotherapy
After confirmation of tumor engraftment, 32 mice were randomized to 4 groups;
BLS only; BLS+NAC; FGS only; and FGS+NAC. Each treatment arm involved 8
tumor-bearing mice. The mice randomized to NAC-treatment were administered
80 mg/kg gemcitabine (GEM) (Eli Lilly and Company, Indianapolis, IN, USA).
GEM was injected i.p. on day 8, 15 and 22. No significant effects on body weight,
morbidity, or severe toxicity were observed in NAC-treated mice.
Fluorescence-guided surgery
For fluorescence-guided surgery (FGS), a 15-mm transverse incision was made on
the left flank of the mouse through the skin and peritoneum which was kept open
with a retractor. The tail of the pancreas was exposed through this incision. Fifty
mg of anti-CA19-9 antibody, conjugated to DyLight 650, was injected via the tail
vein in the mice in the FGS group 24 hours before surgery. A MINI MAGLITE
LED PRO flashlight (MAG INSTRUMENT, Ontario, CA, USA) coupled to an
excitation filter (ET 640/30X, Chroma Technology Corporation, Bellows Falls,
VT, USA) was used as the excitation light source. A Canon EOS 60D digital
camera with an EF–S18–55 IS lens (Canon, Tokyo, Japan) coupled with an
emission filter (HQ700/75M-HCAR, Chroma Technology Corporation) was used
as the real-time image capturing device for FGS. BLS was performed under
standard bright-field using an MVX10 microscope (Olympus, Tokyo, Japan).
After completion of surgery, the incision was closed in one layer using 6-0 nylon
surgical sutures, and the mice were allowed to recover in their cages.
Tissue histology
Tumor samples were removed with surrounding normal tissues at the time of
resection. Fresh tissue samples were fixed in 10% formalin and embedded in
paraffin before sectioning and staining. Tissue sections (3 mm) were deparaffi-
nized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (H &
E) staining was performed according to standard protocols. For immunohis-
tochemistry, the sections were then treated for 30 min with 0.3% hydrogen
peroxide to block endogenous peroxidase activity. The sections were subsequently
washed with PBS and unmasked in citrate antigen unmasking solution
(Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan) in a water bath for 40 min at 98 C˚.
After incubation with 10% normal goat serum, the sections were incubated with
anti-CA19-9 antibody (1:100) and anti-CEA antibody (1:100) at 4 C˚ overnight.
The bound primary antibodies were detected by binding with an anti-mouse
secondary antibody and an avidin/biotin/horseradish peroxidase complex (DAKO
Cytomation, Kyoto, Japan) for 30 min at room temperature. The labeled antigens
were visualized with a DAB kit (DAKO Cytomation). The sections were
counterstained with hematoxylin and observed with a BH-2 microscope
(Olympus, Tokyo, Japan) equipped with an INFINITY1 2.0 megapixel CMOS
digital camera (Lumenera Corporation, Ottawa, Canada). All images were
Neoadjuvant Chemotherapy and Fluorescence Guided Surgery
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acquired using INFINITY ANALYZE software (Lumenera Corporation) without
post-acquisition processing.
Evaluation of histopathological response to NAC
Histopathological response to chemotherapy drugs was defined according to
Evans’s grading scheme: Grade I, little (,10%) or no tumor cell destruction is
evident; Grade IIa, destruction of 10%–50% of tumor cells; Grade IIb, destruction
of 51%–90% of tumor cells; Grade III, few (,10%) viable-appearing tumor cells
are present; Grade IV, no viable tumor cells are present [22].
Evaluation of tumor recurrence and progression
To assess for recurrence postoperatively, animals underwent laparotomy 12 weeks
after surgery, and the tumors were imaged with the Canon EOS 60D digital
camera with an EF–S18–55 IS lens (Canon), excised, harvested and weighed for
analysis.
Figure 1. Antibody labelling of the pancreatic cancer patient derived orthotopic xenograft. The patient’s pancreatic cancer was diagnosed as
moderately differentiated adenocarcinoma with H&E staining (A). The tumor was strongly stained with anti-CA19-9 antibody (B), whereas the signal was
very weak with anti-CEA antibody (C). Scale bars: 100 mm. (D and E) Whole body images of a subcutaneous tumor in nude mice labeled with anti-CA19-9-
or anti-CEA-conjugated DyLight 650. Fifty mg anti-CA19-9 DyLight 650 or anti-CEA DyLight 650 was injected in the tail vain of the mice with subcutaneous
tumors. Twenty-four hours later, whole body images were taken with the OV100 (Olympus). Yellow arrowheads indicate subcutaneous tumors. The
subcutaneous tumors were brightly labeled with anti-CA19-9 DyLight 650 (D), whereas, the fluorescence signal from the tumor labeled with anti-CEA
DyLight 650 was very weak (E). Scale bars: 10 mm.
doi:10.1371/journal.pone.0114310.g001
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Statistical analysis
PASWStatistics 18.0 (SPSS, Inc.) was used for statistical analyses. Tumor weight
was expressed as mean¡ SD. The two-tailed Student’s t-test was used to compare
continuous variables between 2 groups. Comparisons between categorical
variables were analyzed with Fisher’s exact test. A p value ,0.05 was considered
statistically significant for all comparisons.
Figure 2. Experimental schema and FGS imaging system. (A) Schema of the experimental design. After
confirmation of tumor growth, the PDOXs were randomized to 4 groups: BLS only; BLS+NAC; FGS only; or
FGS+NAC. Each treatment arm involved 8 tumor-bearing mice. The mice randomized to the NAC groups
were treated with GEM (80 mg/kg) on day 8, 15 and 22. All animals underwent surgery on day 29. BLS was
performed under standard bright-field using the MVX10 microscope. Fifty mg of anti-CA19-9 antibody
conjugated with DyLight 650 was injected in the tail vain of mice with tumors in the FGS group 24 hours before
surgery. FGS was performed using the MINI MAGLITE LED PRO flash light (MAG INSTRUMENT, Ontario,
CA, USA) with excitation filter ET640/30X (Chroma Technology Corporation, Bellows Falls, VT, USA) and a
Canon EOS 60D digital camera with an EF–S18–55 IS lens (Canon, Tokyo, Japan) and emission filter HQ700/
75M-HCAR (Chroma Technology Corporation) under fluorescence navigation (B). Twelve weeks after
surgery, animals underwent laparotomy, and the tumors were imaged, weighed and harvested for analysis.
Scale bars: 2 cm (filters) and 5 cm (flash light).
doi:10.1371/journal.pone.0114310.g002
Neoadjuvant Chemotherapy and Fluorescence Guided Surgery
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Results
Antibody labeling
The pancreatic PDOX tumor was diagnosed as moderately differentiated
adenocarcinoma with H&E staining (Figure 1A). Based on immunohistochem-
istry, the PDOX tumor was found to be CA19-9-positive and CEA-negative
(Figures 1B and 1C). The PDOX was brightly labeled with anti-CA19-9-650
(Figure 1D), but the fluorescence signal with anti-CEA-650 was very weak
(Figure 1E). The fluorescence results were consistent with the immunohisto-
chemical results, and based on them, it was decided to use anti-CA19-9-650 to
label the PDOX for FGS. Anti-CA19-9-650 was injected in the tail vein of the mice
with PDOX tumors 24 hours before FGS.
Sensitivity of PDOX to NAC
The PDOX mice were randomized to 4 groups; BLS only; BLS+NAC; FGS only;
FGS+NAC. Each treatment arm involved 8 PDOX mice. The mice randomized to
the NAC group were treated with GEM on days 8, 15 and 22 (Figure 2). All
animals underwent surgery on day 29 (Figures 3). The average excised PDOX
tumor weight was 188.5¡53.1 mg for BLS-only; 84.5¡51.6 mg for BLS+NAC;
299.0¡86.3 mg for FGS-only; and 141.8¡48.9 mg for FGS+NAC. The average
excised tumor weight in the BLS+NAC mice was significantly less than in the BLS-
only mice (p50.001). The average excised tumor weight in the FGS+NAC mice
was also significantly less than FGS-only mice (p,0.001). Upon histological
Figure 3. Representative images during FGS with or without NAC. Upper panels indicate bright field (BF)
images and lower panels indicate fluorescence images for DyLight 650 (650). The fluorescence in the tumors
treated with GEM (B) decreased compared to untreated tumors (A), but were still clearly detected. Scale bars:
10 mm.
doi:10.1371/journal.pone.0114310.g003
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examination, over 50% of cancer cells were dead and replaced by necrotic tissue or
stromal cells in the PDOX tumor treated with FGS+NAC and was judged as
Evan’s grade IIb - III (Figure 4).
Effect of NAC on tumor recurrence with BLS or FGS
With regard to the recurrent tumor weight, the average local recurrent tumor
weight was 389.2¡356.6 mg in BLS-only treated mice; 369.1¡251.9 mg in
BLS+NAC-treated mice; 73.0¡77.2 mg in FGS-only treated mice; and
78.4¡90.8 mg in FGS+NAC-treated mice. The average local recurrent tumor
weight in FGS-only treated mice was significantly less than in BLS-only treated
mice (p50.041). The average metastatic recurrent tumor weight of the pancreatic
cancer PDOX was 170.7¡184.2 mg for BLS-only treated mice; 40.0¡19.7 mg for
BLS+NAC-treated mice; 31.3¡37.6 mg for FGS-only mice; and 1.3¡3.7 mg for
FGS+NAC-treated mice. The average metastatic recurrent tumor weight in
FGS+NAC was significantly less than BLS+NAC (p50.001). The metastatic
recurrent weight in the FGS+NAC group compared to the FGS only group was
Figure 4. Representative gross and histological images of excised tumors in each treatment group. Left panels of (A) and (B) indicate bright field (BF)
images and right panels indicate fluorescence images for DyLight 650 (650). Histopathological response to GEM treatment was defined according to
Evans’s grading scheme. The tumors without GEM treatment (FGS only) were comprised of viable cancer cells that formed glandular structures and judged
as Grade I (C). In the tumors with GEM treatment, over 50% of cancer cells were dead and replaced by necrotic tissue or stromal cells (D). Treatment
efficacy of GEM on the pancreatic cancer PDOX was judged as grade IIb - III (D). Fluorescence decreased in some areas of the tumor treated with GEM, but
was sufficient for FGS (B). Scale bars: 5 mm (A and B), 250 mm (C and D).
doi:10.1371/journal.pone.0114310.g004
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marginally significant (0.059). The average total recurrent tumor weight in FGS
only was significantly less than BLS only (p50.037), and that in FGS+NAC was
also significantly less than BLS+NAC (p50.004) (Figures 5 and 6). The
recurrence rate of FGS+NAC was also significantly less than BLS+NAC (p50.008).
FGS+NAC significantly reduced the metastatic recurrence frequency to one of 8
mice compared to FGS only where metastasis recurred in 6 out of 8 mice and
BLS+NAC where it occurred in 7 out of 8 mice (p50.041) (Table 1).
Discussion
In a previous study, we conjugated a monoclonal antibody specific for the tumor-
associated antigen CA19-9 with the AlexaFluor 488 green fluorophore. We were
able to demonstrate in vivo binding of the antibody fluorophore conjugate to the
tumor tissue in an orthotopic mouse model of human pancreatic cancer [5]. This
fluorescence facilitated differentiation between normal and tumor tissue within
Figure 5. Representative images of the recurrent PDOX tumor. (A) A large local recurrent tumor (surrounded by the blue broken line) and peritoneal
dissemination (yellow arrowheads) in a BLS-only treated mouse. (B) A locally recurrent tumor (surrounded by a blue dashed line) and a lymph-node
metastasis in the hepatoduodenal ligament (yellow arrow heads) in a BLS+NAC-treated mouse. (C) A small local recurrent tumor (surrounded by a blue
dashed line) and peritoneal dissemination (yellow arrow heads) in an FGS-only treated mouse. (D) A small local recurrent tumor (surrounded by a blue
dashed line) without metastasis in an FGS+NAC-treated mouse. (E) Gross images of all excised recurrent tumors. Upper lines indicate local recurrent
tumors and lower lines indicate metastatic recurrent tumors. The recurrent tumor volume in the FGS group was smaller than in the BLS group. The
metastatic recurrent tumor volume in the one FGS+NAC-treated mouse that had metastatic recurrence was smaller than recurrent metastases in the FGS-
only treated mice. Scale bars: 10 mm.
doi:10.1371/journal.pone.0114310.g005
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the pancreas and also revealed microscopic foci or tumor implants within the
spleen, liver, and peritoneum which were not visible under standard light
microscopy. This study offered a novel technique to facilitate the intraoperative
identification of both primary tumor and small metastatic lesions that may be
missed at the time of surgery in those patients whose tumors express the tumor-
associated antigen CA19-9.
In another study, we compared a hand-held imaging system with larger imaging
systems previously used for FGS [13]. In a PDOX model labeled with Alexa Fluor
488-conjugated anti-CA 19-9 antibody, only the portable hand-held device could
distinguish the residual tumor from the background, and complete resection of
the residual tumor was achieved under fluorescence navigation, suggesting this
system can be applied to the clinic in the near future to enable widespread
application of FGS.
Figure 6. Recurrent tumor weights for each experimental group. (A) Recurrent tumor weight in the BLS-only; BLS+NAC; FGS-only; and FGS+NAC
treatment groups. The average local recurrent tumor weight for FGS-only treatment was significantly less than for BLS-only treatment (p50.0041). The
average local recurrent tumor weight for FGS+NAC treatment was also significantly less than for BLS+NAC treatment (p50.008). The average metastatic
recurrent tumor weight for FGS+NAC treatment was significantly less than for BLS+NAC treatment (p50.001). FGS+NAC treatment reduced recurrence rate
significantly compared to FGS-only treatment (p50.041) (Table 1). FGS+NAC treatment tended to reduce the metastatic recurrent tumor weight compared
to FGS-only treatment (p50.059).
doi:10.1371/journal.pone.0114310.g006
Table 1. Recurrence rate of PDOX in each treatment group.
local metastatic
BLS only 8/8 (100%) 7/8 (87.5%)
BLS+NAC 8/8 (100%) 7/8 (87.5%)
FGS only 6/8 (75%) 6/8 (75%)
FGS+NAC 6/8 (75%) 1/8 (12.5%)*
* p50.041, compared to FGS only.
doi:10.1371/journal.pone.0114310.t001
Neoadjuvant Chemotherapy and Fluorescence Guided Surgery
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There are several novel aspects to the present study that should be emphasized.
To the best of our knowledge, this is the first study that has utilized the
combination of NAC and a CA 19-9 antibody conjugated fluorophore for FGS of
pancreatic cancer. Furthermore, the present study took advantage of a longer
wavelength dye, DyLight 650, which we have previous shown has better tissue
penetration compared to AlexaFlour 488 [21]. In addition, the PDOX model
developed in our laboratory, and used in the present study, allows for
individualized therapy that is not available with pancreatic cancer cell line models
[7–14, 23]. PDOX models can be helpful to determine if an individual’s tumor is
sensitive to various NAC regimens. The most novel and unexpected finding was
that FGS+NAC eliminated pancreatic cancer metastases in seven out of eight mice.
For bright light surgery, tumors were removed with grossly negative margins
under standard bright-field using an MVX10 microscope. For fluorescence-guided
surgery, tumor resection was guided by labeling the tumors with an anti-CA 19-9
antibody labeled with a 650 nm fluorophore. The pancreatic cancer PDOX used
in this study had a very aggressive behavior. At FGS, we detected some tiny
tumors spreading around the primary tumors, which could not be detected under
normal macroscopic inspection. At the first surgery, the surgical margin was
exterior to the tumor border which was recognized macroscopically. However, a
larger margin provided by FGS appears insufficient to lower or prevent metastatic
recurrence which required NAC in addition to FGS (Table 1). However, the larger
margins afforded by FGS are necessary to lower or prevent metastatic recurrence,
as the combination of BLS and NAC are ineffective to lower or prevent metastatic
recurrence (Table 1).
All mice in this study were euthanized 90 days after BLS or FGS and therefore,
we were not able to compare survival differences between the groups. However, as
seen in Table 1, the metastatic recurrence rate in FGS+NAC was significantly less
than FGS only (p50.041), suggesting that FGS+NAC improves the survival of
pancreatic cancer patients compared to FGS only.
In summary, we have determined the efficacy of NAC with GEM in
combination with FGS on a pancreatic cancer PDOX model. The results from this
study indicate that NAC in combination with FGS can reduce or even eliminate
metastatic recurrence of pancreatic cancer sensitive to NAC. This is an important
result for the future more effective treatment of pancreatic cancer. The present
study further emphasizes the power of the PDOX model which enables metastasis
to occur and thereby identify the efficacy of NAC on metastatic recurrence.
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